Adial Pharmaceuticals Stock Current Liabilities
| ADIL Stock | USD 1.45 0.25 20.83% |
Adial Pharmaceuticals fundamentals help investors to digest information that contributes to Adial Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Adial Stock. The fundamental analysis module provides a way to measure Adial Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Adial Pharmaceuticals stock.
At this time, Adial Pharmaceuticals' Total Current Liabilities is quite stable compared to the past year. Non Current Liabilities Other is expected to rise to about 602.4 K this year, although the value of Non Current Liabilities Total will most likely fall to 415.15. Adial | Current Liabilities |
Adial Pharmaceuticals Company Current Liabilities Analysis
Adial Pharmaceuticals' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Adial Pharmaceuticals Current Liabilities | 452.53 K |
Most of Adial Pharmaceuticals' fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adial Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Adial Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Adial Pharmaceuticals is extremely important. It helps to project a fair market value of Adial Stock properly, considering its historical fundamentals such as Current Liabilities. Since Adial Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Adial Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Adial Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Adial Current Liabilities Historical Pattern
Today, most investors in Adial Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Adial Pharmaceuticals' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Adial Pharmaceuticals current liabilities as a starting point in their analysis.
Adial Pharmaceuticals Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Adial Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Adial Pharmaceuticals has a Current Liabilities of 452.53 K. This is 99.97% lower than that of the Pharmaceuticals sector and 99.92% lower than that of the Health Care industry. The current liabilities for all United States stocks is 99.99% higher than that of the company.
Adial Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Adial Pharmaceuticals' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Adial Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Adial Pharmaceuticals by comparing valuation metrics of similar companies.Adial Pharmaceuticals is currently under evaluation in current liabilities category among related companies.
Adial Fundamentals
| Return On Equity | -1.9 | ||||
| Return On Asset | -0.82 | ||||
| Current Valuation | 3.01 M | ||||
| Shares Outstanding | 4.23 M | ||||
| Shares Owned By Insiders | 4.03 % | ||||
| Shares Owned By Institutions | 7.75 % | ||||
| Number Of Shares Shorted | 132.32 K | ||||
| Price To Earning | (1.88) X | ||||
| Price To Book | 2.31 X | ||||
| EBITDA | (6.89 M) | ||||
| Net Income | (7 M) | ||||
| Cash And Equivalents | 9.16 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 207.38 K | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 5.32 X | ||||
| Book Value Per Share | 2.46 X | ||||
| Cash Flow From Operations | (6.81 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | (4.98) X | ||||
| Target Price | 17.0 | ||||
| Beta | 1.41 | ||||
| Market Capitalization | 6.14 M | ||||
| Total Asset | 4.74 M | ||||
| Retained Earnings | (68.8 M) | ||||
| Working Capital | 2.99 M | ||||
| Current Asset | 1.02 M | ||||
| Current Liabilities | 452.53 K | ||||
| Net Asset | 4.74 M |
About Adial Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Adial Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Adial Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Adial Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Adial Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Adial Pharmaceuticals Piotroski F Score and Adial Pharmaceuticals Altman Z Score analysis. For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Adial Stock analysis
When running Adial Pharmaceuticals' price analysis, check to measure Adial Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adial Pharmaceuticals is operating at the current time. Most of Adial Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Adial Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adial Pharmaceuticals' price. Additionally, you may evaluate how the addition of Adial Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Adial Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.98) | Return On Assets (0.82) | Return On Equity (1.90) |
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.